Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2019

Open Access 01-12-2019 | Mood Disorders | Research

Syndemic factors associated with adherence to antiretroviral therapy among HIV-positive adult heterosexual men

Authors: James M. McMahon, Amy Braksmajer, Chen Zhang, Natalie Leblanc, Michael Chen, Angela Aidala, Janie Simmons

Published in: AIDS Research and Therapy | Issue 1/2019

Login to get access

Abstract

Background

Suboptimal adherence to HIV antiretroviral therapy (ART) and concomitant lack of viral control can have severe consequences for health and onward transmission among persons living with HIV. Little is known about the barriers and facilitators of optimal ART adherence among heterosexual HIV-positive men.

Methods

Structural equation modeling (SEM) was performed to test a theory-derived model of ART adherence using data from a cross-sectional sample of 317 HIV-positive self-identified heterosexual men residing in New York City. We assessed a conceptual model in which mental health (depression, anxiety) and substance use dependence mediated the effects of socio-structural factors (HIV-related stigma, social support) on ART adherence, and subsequently, undetectable viral load.

Results

Structural equation modeling analyses indicated that men who reported higher levels of HIV-related stigma tended to experience higher levels of general anxiety, which in turn was associated with reduced probability of optimal ART adherence. Moreover, men who reported higher levels of social support tended to exhibit less dependence on illicit substance use, which in turn was associated with increased probability of optimal ART adherence. African-American men reported lower ART adherence compared to other racial/ethnic groups.

Conclusions

Our findings support the hypothesis that substance use dependence and mental health problems, particularly anxiety, may be primary drivers of suboptimal ART adherence among heterosexual men, and that socio-structural factors such as HIV-related stigma and social support are potential modifiable antecedents of these drivers.
Literature
1.
Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedCrossRef
2.
Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–9.PubMedCrossRef
3.
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279(24):1977–83.PubMedCrossRef
4.
Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112–8.PubMedCrossRef
5.
Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175–82.PubMedCrossRef
6.
Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564–73.PubMedCrossRef
7.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMedCrossRef
8.
Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus—infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.PubMedCrossRef
9.
Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17):1497–503.PubMedCrossRef
10.
Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRef
11.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentralCrossRef
12.
Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PloS ONE. 2013;8(2):e55747.PubMedPubMedCentralCrossRef
13.
Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Collins S, Mannheimer S, et al. Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals enrolled in the SMART study. Open Forum Infect Dis. 2018;5(1):ofx275.PubMed
14.
Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly active antiretroviral therapy [HAART]: a meta-analysis. AIDS Behav. 2011;15(7):1381–96.PubMedCrossRef
15.
16.
Pool E, Winston A, Bagkeris E, Vera JH, Mallon P, Sachikonye M, et al. High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. HIV Med. 2019;20(2):131–6.PubMed
17.
Jin H, Ogunbajo A, Mimiaga MJ, Duncan DT, Boyer E, Chai P, et al. Over the influence: the HIV care continuum among methamphetamine-using men who have sex with men. Drug Alcohol Depend. 2018;192:125–8.PubMedPubMedCentralCrossRef
18.
Brown MJ, Serovich JM, Laschober TC, Kimberly JA. Age and racial disparities in substance use and self-reported viral suppression among men who have sex with men with HIV. Int J STD AIDS. 2018;29(12):1174–82.PubMedPubMedCentralCrossRef
19.
Chop E, Duggaraju A, Malley A, Burke V, Caldas S, Yeh PT, et al. Food insecurity, sexual risk behavior, and adherence to antiretroviral therapy among women living with HIV: a systematic review. Health Care Women Int. 2017;38(9):927–44.PubMedCrossRefPubMedCentral
20.
Erickson M, Shannon K, Sernick A, Pick N, Ranville F, Martin RE, et al. Women, incarceration and HIV: a systematic review of HIV treatment access, continuity of care and health outcomes across incarceration trajectories. AIDS. 2019;33(1):101–11.PubMedCrossRef
21.
Bazzi AR, Drainoni ML, Biancarelli DL, Hartman JJ, Mimiaga MJ, Mayer KH, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis [PrEP] adherence interventions. BMC Public Health. 2019;19(1):31.PubMedPubMedCentralCrossRef
22.
23.
24.
Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.PubMedCrossRef
25.
26.
Lesko CR, Cole SR, Miller WC, Westreich D, Eron JJ, Adimora AA, et al. Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States. Clin Infect Dis. 2015;60(11):1700–7.PubMedPubMedCentralCrossRef
27.
28.
Folkman S. Commentary on the special section “theory-based approaches to stress and coping” questions, answers, issues, and next steps in stress and coping research. Eur Psychol. 2009;14(1):72–7.CrossRef
29.
Amico KR, Mugavero M, Krousel-Wood MA, Bosworth HB, Merlin JS. Advantages to using social-behavioral models of medication adherence in research and practice. J Gen Intern Med. 2018;33(2):207–15.PubMedCrossRef
30.
Harkness A, Bainter SA, O’Cleirigh C, Mendez NA, Mayer KH, Safren SA. Longitudinal effects of syndemics on ART non-adherence among sexual minority men. AIDS Behav. 2018;22(8):2564–74.PubMedPubMedCentralCrossRef
31.
Quinn KG, Reed SJ, Dickson-Gomez J, Kelly JA. An exploration of syndemic factors that influence engagement in HIV care among Black men. Qual Health Res. 2018;28(7):1077–87.PubMedPubMedCentralCrossRef
32.
Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80.PubMedCrossRef
33.
Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16(2):199–211.PubMedCrossRef
34.
Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17(5):1785–95.PubMedPubMedCentralCrossRef
35.
36.
Janssen MAM, Koopmans PP, Kessels RPC. Cognitive decline in relation to psychological wellbeing and HIV disease- and treatment characteristics in HIV-infected patients on cART: a one-year follow-up study. AIDS Behav. 2017;21(6):1728–34.PubMedCrossRef
37.
Norman LR, Basso M. An update of the review of neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. Curr Drug Abuse Rev. 2015;8(1):50–71.PubMedPubMedCentralCrossRef
38.
Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin N Am. 2007;21(1):181–200, x.PubMedCrossRef
39.
Yang Y, Zhang X, Zhu Y, Dai Y, Liu T, Wang Y. Cognitive impairment in generalized anxiety disorder revealed by event-related potential N270. Neuropsychiatr Dis Treat. 2015;11:1405–11.PubMedPubMedCentral
40.
Nel A, Kagee A. Common mental health problems and antiretroviral therapy adherence. AIDS Care. 2011;23(11):1360–5.PubMedCrossRef
41.
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.PubMedPubMedCentralCrossRef
42.
Thaler NS, Sayegh P, Kim MS, Castellon SA, Hinkin CH. Interactive effects of neurocognitive impairment and substance use on antiretroviral non-adherence in HIV disease. Arch Clin Neuropsychol. 2015;30(2):114–21.PubMedPubMedCentralCrossRef
43.
Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2011;34(2):128–38.PubMedCrossRef
44.
Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMedCrossRef
45.
Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32(5):389–405.PubMedCrossRef
46.
Chandran A, Benning L, Musci RJ, Wilson TE, Milam J, Adedimeji A, et al. The longitudinal association between social support on HIV medication adherence and healthcare utilization in the Women’s Interagency HIV Study. AIDS and Behavior. 2019;23(8):2014–24.PubMedCrossRefPubMedCentral
47.
Kelly JD, Hartman C, Graham J, Kallen MA, Giordano TP. Social support as a predictor of early diagnosis, linkage, retention, and adherence to HIV care: results from the steps study. J Assoc Nurs AIDS Care JANAC. 2014;25(5):405–13.CrossRef
48.
Woodward EN, Pantalone DW. The role of social support and negative affect in medication adherence for HIV-infected men who have sex with men. J Assoc Nurs AIDS Care JANAC. 2012;23(5):388–96.CrossRef
49.
Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.PubMedPubMedCentralCrossRef
50.
Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr, Gardner EM, Macatangay BJ, et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis. 2016;63(12):1661–7.PubMedPubMedCentralCrossRef
51.
Kimmerling M, Wagner G, Ghosh-Dastidar B. Factors associated with accurate self-reported adherence to HIV antiretrovirals. Int J STD AIDS. 2003;14(4):281–4.PubMedCrossRef
52.
Almeida-Brasil CC, Moodie EEM, Cardoso TS, Nascimento ED, Ceccato M. Comparison of the predictive performance of adherence measures for virologic failure detection in people living with HIV: a systematic review and pairwise meta-analysis. AIDS Care. 2019;31(6):647–59.PubMedCrossRef
53.
Sewell J, Daskalopoulou M, Nakagawa F, Lampe F, Edwards S, Perry N, et al. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment. HIV Med. 2017;18(7):463–73.PubMedCrossRef
54.
Sayles JN, Hays RD, Sarkisian CA, Mahagan AP, Spritzer KL, Cunningham WE. Development and psychometric assessment of a multidimensional measure of internalized HIV stigma in a sample of HIV positive adults. AIDS Behav. 2008;12:748–58.PubMedPubMedCentralCrossRef
55.
Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, et al. Performance of an abbreviated version of the Lubben Social Network Scale among three European community-dwelling older adult populations. Gerontologist. 2006;46(4):503–13.PubMedCrossRef
56.
Aidala A, Havens J, Mellins C, Dodds S, Whetten K, Martin D, et al. Development and validation of the Client Diagnostic Questionnaire [CDQ]: a mental health screening tool for use in HIV/AIDS service settings. Psychol Health Med. 2004;9(3):362–80.CrossRef
57.
Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The severity of dependence scale [SDS]: psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–14.PubMedCrossRef
58.
Tsai AC, Burns BF. Syndemics of psychosocial problems and HIV risk: a systematic review of empirical tests of the disease interaction concept. Soc Sci Med. 2015;139:26–35.PubMedPubMedCentralCrossRef
59.
Halkitis PN, Moeller RW, Siconolfi DE, Storholm ED, Solomon TM, Bub KL. Measurement model exploring a syndemic in emerging adult gay and bisexual men. AIDS Behav. 2013;17(2):662–73.PubMedPubMedCentralCrossRef
60.
Wang J, Wang X. Structural equation modeling: applications using Mplus. Hoboken: Wiley; 2012.CrossRef
61.
Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “p < 0.05”. Am Stat. 2019;73:1–19.CrossRef
62.
Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567:305–7.PubMedCrossRef
63.
Shah K, McMahon JM, Trabold N, Aidala AA, Chen M, Pouget ER, et al. Determinants of physical and global functioning in adult HIV-positive heterosexual men. AIDS Care. 2015;27(9):1079–86.PubMedPubMedCentralCrossRef
64.
Braksmajer A, Simmons J, Aidala A, McMahon JM. Effects of discrimination on HIV-related symptoms in heterosexual men of color. Am J Men’s Health. 2018;12(6):1855–63.CrossRef
65.
Crepaz N, Dong X, Wang X, Hernandez AL, Hall HI. Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care—United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67(4):113–8.PubMedPubMedCentralCrossRef
66.
Simoni JM, Huh D, Wilson IB, Shen J, Goggin K, Reynolds NR, et al. Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–72.PubMedPubMedCentralCrossRef
67.
Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39(8):1190–8.PubMedCrossRef
68.
Kline RB. Principles and practice of structural equation modeling. New York: Guilford Publications; 2015.
69.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4).
70.
Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, Skarf LM, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013;30(10):809–19.PubMedCrossRef
71.
Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.PubMedPubMedCentralCrossRef
72.
Babowitch JD, Sheinfil AZ, Woolf-King SE, Vanable PA, Sweeney SM. Association of depressive symptoms with lapses in antiretroviral medication adherence among people living with HIV: a test of an indirect pathway. AIDS Behav. 2018;22(10):3166–74.PubMedCrossRef
73.
Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDs. 2008;22(4):323–35.PubMedCrossRef
74.
Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.PubMedPubMedCentralCrossRef
75.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.PubMedCrossRef
76.
Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdottir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy [ART] for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.PubMedPubMedCentralCrossRef
77.
Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health. 2011;88(3):545–55.PubMedPubMedCentralCrossRef
78.
Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.PubMedPubMedCentralCrossRef
79.
Lehavot K, Huh D, Walters KL, King KM, Andrasik MP, Simoni JM. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patient Care STDs. 2011;25(3):181–9.PubMedPubMedCentralCrossRef
80.
Power R, Koopman C, Volk J, Israelski DM, Stone L, Chesney MA, et al. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care STDs. 2003;17(5):245–52.PubMedCrossRef
81.
Zhang Y, Wilson TE, Adedimeji A, Merenstein D, Milam J, Cohen J, et al. The impact of substance use on adherence to antiretroviral therapy among HIV-infected women in the United States. AIDS Behav. 2018;22(3):896–908.PubMedPubMedCentralCrossRef
82.
Hill LM, Golin CE, Gottfredson NC, Pence BW, DiPrete B, Carda-Auten J, et al. Drug use mediates the relationship between depressive symptoms and adherence to ART among recently incarcerated people living with HIV. AIDS Behav. 2019;23(8):2037–47.PubMedCrossRefPubMedCentral
83.
Wykowski J, Kemp CG, Velloza J, Rao D, Drain PK. Associations between anxiety and adherence to antiretroviral medications in low-and middle-income countries: a systematic review and meta-analysis. AIDS Behav. 2019;23(8):2059–71.PubMedCrossRefPubMedCentral
84.
Blake Helms C, Turan JM, Atkins G, Kempf MC, Clay OJ, Raper JL, et al. Interpersonal mechanisms contributing to the association between HIV-related internalized stigma and medication adherence. AIDS Behav. 2017;21(1):238–47.PubMedCrossRef
85.
Sweeney SM, Vanable PA. The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature. AIDS Behav. 2016;20(1):29–50.PubMedCrossRef
86.
Turan B, Hatcher AM, Weiser SD, Johnson MO, Rice WS, Turan JM. Framing mechanisms linking HIV-related stigma, adherence to treatment, and health outcomes. Am J Public Health. 2017;107(6):863–9.PubMedPubMedCentralCrossRef
87.
Turan B, Smith W, Cohen MH, Wilson TE, Adimora AA, Merenstein D, et al. Mechanisms for the negative effects of internalized HIV-related stigma on antiretroviral therapy adherence in women: the mediating roles of social isolation and depression. J Acquir Immune Defic Syndr. 2016;72(2):198–205.PubMedPubMedCentralCrossRef
88.
Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2012;16(3):711–6.PubMedPubMedCentralCrossRef
89.
Mitzel LD, Vanable PA, Brown JL, Bostwick RA, Sweeney SM, Carey MP. Depressive symptoms mediate the effect of HIV-related stigmatization on medication adherence among HIV-infected men who have sex with men. AIDS Behav. 2015;19(8):1454–9.PubMedCrossRef
90.
Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–8.PubMedPubMedCentralCrossRef
91.
Shrestha R, Altice FL, Copenhaver MM. HIV-related stigma, motivation to adhere to antiretroviral therapy, and medication adherence among HIV-positive methadone-maintained patients. J Acquir Immune Defic Syndr. 2019;80(2):166–73.PubMedCrossRefPubMedCentral
92.
Seghatol-Eslami VC, Dark HE, Raper JL, Mugavero MJ, Turan JM, Turan B. Brief report: interpersonal and intrapersonal factors as parallel independent mediators in the association between internalized HIV stigma and ART adherence. J Acquir Immune Defic Syndr. 2017;74(1):e18–22.PubMedPubMedCentralCrossRef
93.
DiIorio C, McCarty F, DePadilla L, Resnicow K, Holstad MM, Yeager K, et al. Adherence to antiretroviral medication regimens: a test of a psychosocial model. AIDS Behav. 2009;13(1):10–22.PubMedCrossRef
94.
Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124–33.PubMedCrossRef
95.
Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care. 2004;16(4):471–84.PubMedCrossRef
96.
Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedCrossRef
97.
Berghoff CR, Gratz KL, Portz KJ, Pinkston M, Naifeh JA, Evans SD, et al. The role of emotional avoidance, the patient-provider relationship, and other social support in ART adherence for HIV+ individuals. AIDS Behav. 2018;22(3):929–38.PubMedCrossRef
98.
Simoni JM, Frick PA, Huang B. A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. Health Psychol. 2006;25(1):74–81.PubMedPubMedCentralCrossRef
99.
Cook PF, Schmiege SJ, Bradley-Springer L, Starr W, Carrington JM. Motivation as a mechanism for daily experiences’ effects on HIV medication adherence. J Assoc Nurs AIDS Care JANAC. 2018;29(3):383–93.CrossRef
100.
Atkinson JS, Schonnesson LN, Williams ML, Timpson SC. Associations among correlates of schedule adherence to antiretroviral therapy [ART]: a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection. AIDS Care. 2008;20(2):253–62.PubMedPubMedCentralCrossRef
101.
Gonzalez JS, Penedo FJ, Antoni MH, Duran RE, McPherson-Baker S, Ironson G, et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004;23(4):413–8.PubMedCrossRef
102.
Vyavaharkar M, Moneyham L, Tavakoli A, Phillips KD, Murdaugh C, Jackson K, et al. Social support, coping, and medication adherence among HIV-positive women with depression living in rural areas of the southeastern United States. AIDS Patient Care STDs. 2007;21(9):667–80.PubMedCrossRef
103.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDs. 2015;29(3):111–6.PubMedPubMedCentralCrossRef
104.
Aidala AA, Wilson MG, Shubert V, Gogolishvili D, Globerman J, Rueda S, et al. Housing status, medical care, and health outcomes among people living with HIV/AIDS: a systematic review. Am J Public Health. 2016;106(1):e1–23.PubMedPubMedCentralCrossRef
105.
Singer AW, Weiser SD, McCoy SI. Does food insecurity undermine adherence to antiretroviral therapy? A systematic review. AIDS Behav. 2015;19(8):1510–26.PubMedCrossRef
106.
Emlet CA, Brennan DJ, Brennenstuhl S, Rueda S, Hart TA, Rourke SB. The impact of HIV-related stigma on older and younger adults living with HIV disease: does age matter? AIDS Care. 2015;27(4):520–8.PubMedCrossRef
107.
Mavandadi S, Zanjani F, Ten Have TR, Oslin DW. Psychological wellbeing among individuals aging with HIV: the value of social relationships. J Acquir Immune Defic Synd. 2009;51(1):91.CrossRef
108.
Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242–57.PubMedCrossRef
Metadata
Title
Syndemic factors associated with adherence to antiretroviral therapy among HIV-positive adult heterosexual men
Authors
James M. McMahon
Amy Braksmajer
Chen Zhang
Natalie Leblanc
Michael Chen
Angela Aidala
Janie Simmons
Publication date
01-12-2019
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2019
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-019-0248-9

Other articles of this Issue 1/2019

AIDS Research and Therapy 1/2019 Go to the issue

Short Report

Repeat HIV testing of individuals with discrepant HIV self-test results in Central Uganda

Review

Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research

Research

Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up

Review

Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?

Research

Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study

Research

Feasibility and yield of HIV screening among adult trauma patients presenting to an urban emergency department of a tertiary referral hospital in Tanzania
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits